[Optimal platelet inhibition therapy in unstable angina pectoris and after coronary interventions]

Area of Science:

• Cardiology
• Pharmacology

Background:

• Unstable angina pectoris (UAP) poses significant risks of myocardial infarction.
• Aspirin demonstrates efficacy in reducing cardiovascular events in UAP.
• The optimal aspirin dosage for UAP remains under investigation.

Purpose of the Study:

• To review the efficacy of antithrombotic therapies in unstable angina.
• To evaluate the role of aspirin, heparin, and thienopyridine derivatives.
• To provide therapeutic recommendations post-coronary intervention.

Main Methods:

• Review of existing studies on antithrombotic agents in unstable angina.
• Comparison of aspirin monotherapy versus combination therapies.
• Assessment of thienopyridine derivatives (ticlopidine, clopidogrel) efficacy.
• Evaluation of antiplatelet therapy for preventing coronary stent thrombosis.

Main Results:

• Aspirin significantly reduces myocardial infarction rates in unstable angina.
• Aspirin-heparin combination therapy is more effective than aspirin alone.
• Ticlopidine shows superiority over aspirin monotherapy in unstable angina.
• Clopidogrel combined with aspirin is effective in preventing coronary stent thrombosis.
• Clopidogrel is preferred over ticlopidine due to a better safety profile.

Conclusions:

• Aspirin and heparin form the basis of antithrombotic therapy for unstable angina.
• Clopidogrel, in combination with aspirin, is the recommended treatment for at least four weeks post-coronary stenting.